Research and Clinical Trials on Atomoxetine (Strattera)

Atomoxetine (Strattera) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Atomoxetine (Strattera).

• Effectiveness of Atomoxetine in Treating Attention Deficit Hyperactivity Disorder Symptoms in Children and Adolescents With Autism
  Status: Recruiting, Condition Summary: Autism
• Atomoxetine and Parent Management Training in Treating Children With Autism and Symptoms of Attention Deficit Disorder With Hyperactivity
  Status: Recruiting, Condition Summary: Autism; Attention Deficit Disorder With Hyperactivity
• Effects of Atomoxetine on Brain Activation During Attention and Reading Tasks in Patients With ADHD & Comorbid Dyslexia
  Status: Not yet recruiting, Condition Summary: Attention Deficit Hyperactivity Disorder; Dyslexia
• Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
  Status: Active, not recruiting, Condition Summary: Attention Deficit Disorder With Hyperactivity
• Atomoxetine Asian Study in Adult Subjects With ADHD
  Status: Recruiting, Condition Summary: Attention Deficit Hyperactivity Disorder
• Treatment of ADHD With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
  Status: Recruiting, Condition Summary: Attention Deficit/Hyperactivity Disorder
• Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE
  Status: Not yet recruiting, Condition Summary: Attention Deficit Hyperactivity Disorder; Cannabis Abuse
• Comparison of Atomoxetine Versus Placebo in Children With ADHD
  Status: Recruiting, Condition Summary: Attention Deficit Hyperactivity Disorder
• Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
  Status: Completed, Condition Summary: Attention Deficit Disorder With Hyperactivity
• Atomoxetine Effects in Humans
  Status: Active, not recruiting, Condition Summary: Physiological Stress
• Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)
  Status: Recruiting, Condition Summary: Traumatic Brain Injury
• Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)
  Status: Recruiting, Condition Summary: ADHD NOS
• Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
  Status: Completed, Condition Summary: Schizophrenia
• Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder
  Status: Recruiting, Condition Summary: Generalized Social Anxiety Disorder
• The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents
  Status: Recruiting, Condition Summary: Attention Deficit Hyperactivity Disorder; Insomnia

 

Get These Clinical Trials as a Newsfeed

Atomoxetine:             

Current Research Literature on Atomoxetine (Strattera)

Here are abstracts for some of the latest research articles to have appeared on Atomoxetine (Strattera):

The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database.

Curr Drug Saf. 2008 May; 3(2): 123-31
McAfee AT, Holdridge KC, Johannes CB, Hornbuckle K, Walker AM
Purpose: To estimate the rate of new-onset seizure in ADHD patients in relation to ADHD pharmacotherapy. Methods: A retrospective cohort study of 34,727 patients, ages 6 to 17, with at least two insurance claims bearing ADHD diagnoses during 2003 in the UnitedHealthcare database. Incidence of seizure was calculated for observation time during treatment with atomoxetine and stimulants/bupropion. Results: Seizure incidence among ADHD patients was 4.5/1,000 person-years (p-y; 95% confidence interval 3.7 - 5.5). ADHD patients who received any ADHD medication had an incidence of 3.8/1,000 p-y (3.0 - 4.8) compared to 8.7 (5.8 - 12.4) for patients who did not receive any ADHD medication. The relative risk (RR) for current vs non-use of atomoxetine was 1.1 (0.6 - 2.1). For stimulants and bupropion, the RR for current vs non-use was 0.8 (0.6 - 1.3). Elevated seizure risks were found in association with central nervous system (CNS) disease (OR 3.9, 1.2 - 10.9), CNS medications (OR 2.2, 1.3 - 3.6), metabolic disease (OR 2.9, 1.1 - 6.8), and psychiatric disease risk factors (OR 1.7, 1.1 - 2.6). Conclusions: In this study, there was no statistically significant association between use of atomoxetine or stimulants and seizure risk in children ages 6 to 17 years with ADHD and without prior seizure disorder.

Atomoxetine-associated hemospermia: a case report.

J Clin Psychiatry. 2008 Jul; 69(7): 1189
Raj YP

Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.

Bioorg Med Chem Lett. 2008 Aug 15; 18(16): 4491-4
Hudson S, Kiankarimi M, Eccles W, Dwight W, Mostofi YS, Genicot MJ, Fleck BA, Gogas K, Aparicio A, Wang H, Wen J, Wade WS
The synthesis and SAR of a series of chiral heterocyclic ring-constrained norepinephrine reuptake inhibitors are described. The best compounds compare favorably with atomoxetine in potency (IC(50)s1 microM). In addition, the compounds are generally more stable than atomoxetine to oxidative metabolism and thus are likely to have lower clearance in humans.

Nucleophilic Addition of Phenol Derivatives to Methyl 1-Nitrocyclopropanecarboxylates.

J Org Chem. 2008 Aug 1;
Lifchits O, Alberico D, Zakharian I, Charette AB
Nucleophilic ring opening of methyl 1-nitrocyclopropanecarboxylates by phenol derivatives in the presence of Cs 2CO 3 is described. The reaction tolerates a variety of substituents on both the aromatic alcohol and the cyclopropane and affords the products in good yields (53-84%) and with complete preservation of the enantiomeric excess at C-4. The methodology was applied in an enantioselective synthesis of the norepinephrine reuptake inhibitor atomoxetine (Strattera).

Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.

Bioorg Med Chem Lett. 2008 Aug 15; 18(16): 4495-8
Hudson S, Kiankarimi M, Eccles W, Mostofi YS, Genicot MJ, Dwight W, Fleck BA, Gogas K, Wade WS
The design, synthesis and SAR of a series of heterocyclic ring-constrained norepinephrine reuptake inhibitors are described. As racemates, the best compounds compare favorably with atomoxetine (IC(50)'s